ALT Altimmune Inc

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025.

Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at .

Participants who would like to join the call may register to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Company Contact:

Greg Weaver

Chief Financial Officer

Phone: 240-654-1450

Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403

Media Contact:

Jake Robison

Inizio Evoke, Biotech

Phone: 619-849-5383

This press release was published by a CLEAR® Verified individual.



EN
06/05/2025

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Multiple Presentations at Upcoming American Diabet...

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association’s (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under d...

June 13, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the...

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual recep...

May 19, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune to Participate at Two Upcoming Investor Conferences GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)Tuesday, May 20, 2025Fireside Chat at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference (New Y...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Secures Up to $100 Million in Credit Facility from Hercules ...

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital Term loan adds balance sheet strength and provides financial flexibility to support continued development of pemvidutide GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE: HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility...

May 13, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces First Quarter 2025 Financial Results and Business ...

Altimmune Announces First Quarter 2025 Financial Results and Business Update Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch